Covered recipient · General Payments record
JULIET ARAMBULO COQUIA
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2022
$1,963.73
- Reported across 52 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2022 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $999.81 | 17 |
By paying entity
PY2022 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $292.03 | 8 |
| Janssen Scientific Affairs, LLC | $221.26 | 2 |
| Aurinia Pharma U.S., Inc. | $122.09 | 1 |
| Actelion Pharmaceuticals US, Inc. | $121.36 | 1 |
| Acerta Pharma LLC | $95.91 | 1 |
| UCB, Inc. | $89.15 | 1 |
| Lilly USA, LLC | $21.95 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.38 | 1 |
| PFIZER INC. | $15.68 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2022 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $121.36 | 07/12/2022 | Food and Beverage | Undisputed | 01/23/2026 | 885403103 | CMS |
| Amgen Inc. | $7.56 | 01/12/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939218887 | CMS |
| Amgen Inc. | $11.26 | 02/15/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939218889 | CMS |
| Amgen Inc. | $5.97 | 05/04/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939218893 | CMS |
| Amgen Inc. | $14.30 | 05/10/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939218895 | CMS |
| Amgen Inc. | $125.00 | 05/11/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939848971 | CMS |
| Amgen Inc. | $109.76 | 06/22/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939218897 | CMS |
| Amgen Inc. | $9.11 | 06/29/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939218885 | CMS |
| Amgen Inc. | $9.07 | 07/13/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939218891 | CMS |
| AstraZeneca Pharmaceuticals LP | $95.91 | 04/07/2022 | Food and Beverage | Undisputed | 01/23/2026 | 920247861 | CMS |
| Aurinia Pharma U.S., Inc. | $122.09 | 06/24/2022 | Food and Beverage | Undisputed | 01/23/2026 | 954071485 | CMS |
| Janssen Scientific Affairs, LLC | $111.32 | 05/19/2022 | Food and Beverage | Undisputed | 01/23/2026 | 887235597 | CMS |
| Janssen Scientific Affairs, LLC | $109.94 | 07/21/2022 | Food and Beverage | Undisputed | 01/23/2026 | 887235603 | CMS |
| Lilly USA, LLC | $21.95 | 03/31/2022 | Food and Beverage | Undisputed | 01/23/2026 | 918113781 | CMS |
| Novartis Pharmaceuticals Corporation | $20.38 | 06/27/2022 | Food and Beverage | Undisputed | 01/23/2026 | 893582487 | CMS |
| PFIZER INC. | $15.68 | 07/12/2022 | Food and Beverage | Undisputed | 01/23/2026 | 949564227 | CMS |
| UCB, Inc. | $89.15 | 06/29/2022 | Food and Beverage | Undisputed | 01/23/2026 | 908123025 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.